We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01260779
Recruitment Status : No longer available
First Posted : December 15, 2010
Last Update Posted : July 11, 2016
Information provided by (Responsible Party):

December 13, 2010
December 15, 2010
July 11, 2016
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
This compassionate use protocol provides expanded access for investigational use of PV-10 in cancer patients who are not eligible for an existing PV-10 clinical trial, for whom there is no comparable or satisfactory approved alternative therapy and whom, in the opinion of the investigator, may benefit from PV-10 administration.
Not Provided
Expanded Access
Drug: PV-10 (10% rose bengal disodium)
Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
Not Provided
No longer available
Contact information is only displayed when the study is recruiting subjects
Australia,   United States
Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )
Provectus Biopharmaceuticals, Inc.
Not Provided
Not Provided
Provectus Pharmaceuticals
July 2016